Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASR | P41180 | 11/20 | 0.65 |
| ▸ | HTR5A | P47898 | 1/20 | 0.56 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.53 |
| ▸ | HTR1A | P08908 | 1/20 | 0.53 |
| ▸ | DRD2 | P14416 | 1/20 | 0.53 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.44 |
| ▸ | NPC1 | O15118 | 1/20 | 0.44 |
| ▸ | RAB9A | P51151 | 1/20 | 0.44 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4993611 | 1.00 | CASR (0.65) | CASRHTR5AABCB1HTR1ADRD2 | |
| SCHEMBL2458679 | 0.86 | CASR (0.65) | CASRHTR5AHTR1AMEN1KMT2A | |
| SCHEMBL3926119 | 0.81 | CASR (0.68) | CASRHTR5AHTR1ANPC1RAB9A | |
| SCHEMBL3962711 | 0.80 | HTR5A (0.55) | CASRHTR5AABCB1HTR1ADRD2 | |
| SCHEMBL8199702 | 0.80 | HTR5A (0.55) | CASRHTR5AABCB1HTR1ADRD2 | |
| SCHEMBL15130965 | 0.79 | CASR (0.82) | CASRHTR5AHTR1AMEN1KMT2A | |
| SCHEMBL13868194 | 0.79 | CASR (0.62) | CASRHTR5AHTR1A | |
| SCHEMBL791890 | 0.78 | FFAR1 (0.61) | ABCB1HTR1ADRD2MAOBNPC1 | |
| SCHEMBL5267428 | 0.77 | MEN1 (0.70) | CASRMEN1KMT2AALDH1A1BCHE | |
| SCHEMBL5267733 | 0.77 | MEN1 (0.70) | CASRMEN1KMT2AALDH1A1BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-8349831-B2 | Osteoporosis, bone disorders, or diseases associated with excessive secretion of PTH, such as hyperparathyroidism; reduce or inhibit parathyroid hormone (PTH) secretion | AMGEN INC. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| US-20080221101-A1 | Calcium receptor modulating agents | AMGEN INC. (US) | 2008-09-11 | — | — | US | disclosed |
| WO-2008057282-A1 | CALCIUM RECEPTOR MODULATING AGENTS | AMGEN INC. (US) | 2008-05-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080221101-A1 | Calcium receptor modulating agents | CASR, RYR1, RYR2 | CASR 1/4885HTR5A 397/4885ABCB1 1568/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.